JOJuan Ortiz-Álvarez

Juan Ortiz-Álvarez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Ortiz-Álvarez has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adalimumab-related Spondylodiscitis: A Side Effect to be Taken into Consideration

    by J. Ortiz-Álvarez, L. Rodríguez Fernandez-Freire, M. Morillo Andújar, J. Conejo-Mir Sánchez


  • Open Access

    Hospitalizations Due to Hidradenitis Suppurativa in Spain Between 2016 and 2021: Demographic and Stratified Analysis by Sex for a Population Cohort

    by J. Ortiz-Álvarez, J.J. Pereyra-Rodríguez, J. Conejo-Mir Sánchez, G. Osorio Gómez

  • Skin Health for All: Improving Dermatological Care for Migrants and Underserved Populations in Malta and Greece

    by Amna Elyas, Juan Ortiz‐Alvarez, Isotta Rossoni, Apostolos Veizis, Valeska Padovese


  • Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice

    by Guiovana Fernanda Osorio‐Gómez, Juan Ortiz‐Álvarez, Delia Diaz‐Ceca, Cesar Guijarro‐Sánchez, Julián Conejo‐Mir Sánchez, Pablo Fernández Crehuet

    Introduction: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF‐alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL‐17, thus having a promising role in the treatment of HS.Material and methods: A multicenter retrospective observational open‐label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow‐up time. Demographic and disease‐related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.Results: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.Conclusions: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.


  • Genetic and dermoscopic findings in a case series of children with oculocutaneous albinism

    by Juan Manuel Liñán‐Barroso, María Eugenia Mantrana‐Bermejo, Antonio José Durán‐Romero, Juan Ortiz‐Álvarez, María Teresa Monserrat‐García, Guillermo José Jiménez‐Thomas, Julián Conejo‐Mir Sánchez, José Bernabéu‐Wittel

    Oculocutaneous albinism (OCA) is a genetic disease caused by disorders in melanin synthesis or distribution. In this descriptive study conducted in a tertiary care pediatric hospital, patients with a clinical diagnosis of OCA and genetic study were retrospectively recruited and underwent dermatological and ophthalmological exam, including optical coherence tomography (OCT) and digital dermoscopy. Our findings revealed milder OCA phenotypic expression in individuals harboring single pathogenic mutations in conjunction with polymorphisms, as well as in those with mutations of uncertain significance. Regardless OCA subgroup, severe phenotypes of OCA were associated with a higher number of mutations/polymorphisms in melanin biosynthesis genes and paler dermoscopic patterns, such as vascular pattern, which was the most common pattern in our series.


  • Open Access

    Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice

    by Guiovana Fernanda Osorio-Gómez, Juan Ortiz-Álvarez, Julián Conejo-Mir Sánchez, Pablo Fernández-Crehuet

    Introduction The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. Material and methods A multicenter longitudinal observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at week 0 and week 16. Demographic and disease-related variables as well as response parameters (HiSCR, IHS4 and PGA) and safety were recorded and analyzed. Results A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in 3 patients with no fatal outcomes and treatment discontinuation was advised in 4 patients. Conclusions Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.

  • Open Access

    Prediction of melanoma Breslow thickness using deep transfer learning algorithms

    by Juan-Carlos Hernández-Rodríguez, Lourdes Durán-López, Juan P Domínguez-Morales, Juan Ortiz-Álvarez, Julián Conejo-Mir, Jose-Juan Pereyra-Rodriguez

    Background: The distinction between in situ melanoma (MIS) and invasive melanoma is challenging even for expert dermatologists. The use of pretrained convolutional neural networks (CNNs) as ancillary decision systems needs further research. Aim: To develop, validate and compare three deep transfer learning (DTL) algorithms to predict MIS vs. invasive melanoma and melanoma with a Breslow thickness (BT) of < 0.8 mm vs. ≥ 0.8 mm. Methods: A dataset of 1315 dermoscopic images of histopathologically confirmed melanomas was created from Virgen del Rocio University Hospital and open repositories of the International Skin Imaging Collaboration archive and Polesie S et al. (Dermatol Pract Concept 2021; 11:e2021079). The images were labelled as MIS or invasive melanoma and < 0.8 mm or ≥ 0.8 mm of BT. We conducted three trainings, and overall means for receiver operating characteristic (ROC) curves, sensitivity, specificity, positive and negative predictive value, and balanced diagnostic accuracy outcomes were evaluated on the test set with ResNetV2, EfficientNetB6 and InceptionV3. The results of 10 dermatologists were compared with the algorithms. Grad-CAM gradient maps were generated, highlighting relevant areas considered by the CNNs within the images. Results: EfficientNetB6 achieved the highest diagnostic accuracy for the comparison between MIS vs. invasive melanoma (61%) and BT < 0.8 mm vs. ≥ 0.8 mm (75%). For the BT comparison, ResNetV2 with an area under the ROC curve of 0.76 and InceptionV3 with an area under the ROC curve of 0.75, outperformed the results obtained by the dermatologist group with an area under the ROC curve of 0.70. Conclusion: EfficientNetB6 recorded the best prediction results, outperforming the dermatologists for the comparison of 0.8 mm of BT. DTL could be an ancillary aid to support dermatologists’ decisions in the near future.


  • Open Access

    Skin cancer mortality in Spain: adjusted mortality rates by province and related risk factors

    by Antonio Alcalá Ramírez del Puerto, Juan Carlos Hernández‐Rodriguez, Mercedes Sendín‐Martín, Juan Ortiz‐Alvarez, Julián Conejo‐Mir Sánchez, José Juan Pereyra‐Rodriguez

    Background: Ultraviolet radiation is the main environmental risk factor responsible for the development of skin cancer. Other occupational, socioeconomic, and environmental factors appear to be related to the risk of skin cancer. Furthermore, the factors appear to differ for melanoma and non‐melanoma skin cancer (NMSC). The purpose of this study is to analyze mortality rates of skin cancer in the different provinces of Spain and to determine the influence of socioeconomic conditions and other environmental and demographic factors in rates.Methods: Deaths from melanoma and NMSC in the period 2000–2019 were obtained as well as socioeconomic and environmental variables. Annual standardized mortality rates (SMR) were calculated for all Spanish provinces. The Pearson correlation coefficient was calculated.Results: The SMR of melanoma was 2.10/100,000 inhabitants, while that of NMSC was 1.28/100,000. At the provincial level, a great variability is confirmed. Gross domestic product showed a positive correlation with melanoma mortality but a negative correlation with NMSC. Other environmental and socioeconomic variables also showed correlation, as a positive correlation between tobacco sales and melanoma and between agricultural development and the NMSC.Conclusions: There are still important differences between each province that must be taken into account when planning health care and resource distribution. This ecological and province‐wise study helps to elucidate the relationship between social and ambient exposure determinants and skin cancer mortality in Spain.